IP Library › Granted Patent US 12,447,145
Granted Patent B2
US 12,447,145 · App. 17/281,659 · Granted Oct 21, 2025

Compositions and methods for treating inflammatory neurological disorders

Inventors: Jeffrey Huang (Bethesda, MD); Maryna Baydyuk (Springfield, VA)
Assignee: Georgetown University
A61K31/423A61K9/0019
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,447,145
App. No.
17/281,659
Granted
Oct 21, 2025
Kind
B2
Abstract

The present application is directed to methods and compositions for treating a condition marked by enhanced inflammation in the central nervous system (CNS). The methods comprise administering to a subject in need of treatment of enhanced inflammation in the CNS an inhibitor of an amino acid transporter in inflammatory cells present in the CNS. The compositions of the present invention relate to compositions comprising an inhibitor of an amino acid transporter in inflammatory cells, or a pharmaceutically acceptable salt thereof, wherein the composition is formulated for direct administration into the CNS of a mammal.

Claims (13)

1. A method of promoting remyelination of neurons in the central nervous system (CNS) in a condition marked by enhanced inflammation in the CNS and demyelination of neurons of a subject, the method comprising administering to the subject an inhibitor of large amino acid transporter small subunit 1 (LAT1) protein,

wherein the inhibitor inhibits LAT1 protein in microglia, macrophages, B-cells, or a combination thereof, present in the CNS.

2. The method of claim 1 , wherein the condition is selected from the group consisting of multiple sclerosis (MS), inflammatory demyelinating disease, stroke, acute disseminated encephalomyelitis (ADEM), traumatic brain injury (TBI), viral infection, spinal cord injury, optic nerve injury, and cerebral palsy.

3. The method of claim 1 , wherein condition is MS.

4. The method of claim 1 , wherein the condition is autoimmune encephalitis.

5. The method of claim 1 , wherein the inhibitor inhibits LAT1 protein in microglia, macrophages, or a combination thereof.

6. The method of claim 5 , wherein the inhibitor inhibits LAT1 protein in microglia.

7. The method of claim 1 , wherein the inhibitor is JPH203 or a pharmaceutically acceptable salt thereof.

8. The method of any of claim 1-6 or 7 , wherein the inhibitor is administered systemically.

9. The method of claim 8 , wherein the route of systemic administration is selected from the group consisting of intravenously, orally, intraperitoneally, intramuscularly, intradermally, intrathecally, subcutaneously and nasally.

10. The method of any of claim 1-6 or 7 , wherein the inhibitor of the amino acid transporter is administered locally to the CNS.

11. The method of any of claim 1-6 or 7 , wherein the subject is a mammal.

12. The method of any of claim 1-6 or 7 , wherein the inhibitor of an amino acid transporter is administered more than once.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 19, 2025
From: HUANG, JEFFREY; BAYDYUK, MARYNA
To: GEORGETOWN UNIVERSITY
Reel/Frame 072063/0985 →
CONFIRMATORY LICENSE Recorded Aug 9, 2023
From: GEORGETOWN UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 064543/0984 →
Continuity (2)
Provisional Application 62740175 · Oct 2, 2018
Related Publication 20220000842A1 · Jan 6, 2022
References Cited (24)
US 20150336876A1 · Kanai et al. · 2015 [cited by applicant]
US 20160120830A1 · Heresco-Levy · 2016 [cited by applicant]
JP 2017155023A · 2017 [cited by applicant]
Wikipedia âExperimental autoimmune encephalomyelitisa <https://en.wikipedia.org/wiki/Experimental_autoimmune_encephalomyelitis> captured via Wayback Machine® Mar. 5, 2018 (Year: 2018). [cited by examiner]
Michael F. Wempe, et al., “Metabolism and Pharmacokinetic Studies of JPH203, an L-Amino Acid Transporter 1 (LAT1) Selective Compound,” Drug Metabolism and Pharmacokinetics, Sep. 13, 2011, pp. 155-161, vol. 27, No. 1. [cited by applicant]
Koji Oda, et al., “L-Type Amino Acid Transporter 1 Inhibitors Inhibit Tumor Cell Growth,” Cancer Science, Dec. 9, 2009, pp. 173-179, vol. 101, No. 1. [cited by applicant]
Palanivel Kandasamy, et al., “Amino Acid Transporters Revisited: New Views in Health and Disease,” Trends in Biochemical Sciences, Oct. 2018, pp. 752-789, vol. 43, No. 10. [cited by applicant]
Keitaro Hayashi, et al., “LAT1 is a Critical Transporter of Essential Amino Acids for Immune Reactions in Activated Human T Cells,” The Journal of Immunology, Sep. 13, 2013, pp. 4080-4085, vol. 191, No. 8. [cited by applicant]
International Search Report and Written Opinion of the International Searching Authority in International Application No. PCT/US2019/054245, dated Jan. 6, 2020. [cited by applicant]
Ren et al., Amino-Acid Transporters in T-Cell Activation and Differentiation, Cell Death and Disease, Mar. 2, 2017, e2655, vol. 8. [cited by applicant]
Huttunen et al., A Selective and Slowly Reversible Inhibitor of L-Type Amino Acid Transporter 1 (LAT1) Potentiates Antiproliferative Drug Efficacy in Cancer Cells, Journal of Medicinal Chemistry, Jun. 2, 2016, pp. 5740-… [cited by applicant]
Natesh Singh, et al., “Discovery of Potent Inhibitors for the Large Neutral Amino Acid Transporter 1 (LAT1) by Structure-Based Methods”, International Journal of Molecular Sciences, 2019, p. 27, vol. 20, No. 1. [cited by applicant]
Magdalena Markowicz-Piasecka, et al., “Hemocompatible LAT1-Inhibitor Can Induce Apoptosis in Cancer Cells without Affecting Brain Amino Acid Homeostasis”, Apoptosis, 2020, pp. 426-440, vol. 25, Nos. 5-6. [cited by applicant]
Cris S. Constantinescu, et al., “Experimental Autoimmune Encephalomyelitis (EAE) as a Model for Multiple Sclerosis (MS)”, British Journal of Pharmacology, 2011, pp. 1079-1106, vol. 164, No. 4. [cited by applicant]
Ryan J. Bevan, et al., “Meningeal Inflammation and Cortical Demyelination in Acute Multiple Sclerosis”, Annals of Neurology, 2018, pp. 829-842, vol. 74, No. 6. [cited by applicant]
Roberta Magliozzi, et al., “Meningeal B-cell Follicles in Secondary Progressive Mutiple Sclerosis Associate with Early Onset of Disease and Severe Cortical Pathology”, Brain, 2007, pp. 1089-1104, vol. 130, part 4. [cited by applicant]
Roberta Magliozzi, et al., “A Gradient of Neuronal Loss and Meningeal Inflammation in Multiple Sclerosis”, Annals of Neurology, 2010, pp. 477-493, vol. 68, No. 4. [cited by applicant]
Yvonne Dombrowski, et al., “Regulatory T Cells Promote Myelin Regeneration in the Central Nervous System”, Nature Neuroscience, 2017, pp. 674-680, vol. 20, No. 5. [cited by applicant]
Andrea Pennati, et al., “Regulatory B Cells Normalize CNS Myeloid Cell Content in a Mouse Model of Multiple Sclerosis and Promote Oligodendrogenesis and Remyelination”, Journal of Neuroscience, 2020, pp. 5105-5115, vol.… [cited by applicant]
Natesh Singh, et al., “Discovery of Potent Inhibitors for the Large Neutral Amino Acid . . . ”, International Journal of Molecular Sciences, 2019, p. 27, vol. 20, No. 1. [cited by applicant]
Magdalena Markowicz-Piasecka, et al., “Hemocompatible LAT1-Inhibitor Can Induce Apoptosis in Cancer Cells without . . . ”, Apoptosis, 2020, pp. 426-440, vol. 25, Nos. 5-6. [cited by applicant]
Cris S. Constantinescu, et al., “Experimental Autoimmune Encephalomyelitis (EAE) as a Model . . . ”, British Journal of Pharmacology, 2011, pp. 1079-1106, vol. 164, No. 4. [cited by applicant]
Roberta Magliozzi, et al., “Meningeal B-cell Follicles in Secondary Progressive Mutiple Sclerosis Associate with Early . . . ”, Brain, 2007, pp. 1089-1104, vol. 130, part 4. [cited by applicant]
Andrea Pennati, et al., “Regulatory B Cells Normalize CNS Myeloid Cell Content in a Mouse Model of . . . ”, Journal of Neuroscience, 2020, pp. 5105-5115, vol. 40, No. 26. [cited by applicant]